Abstract
Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight- Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Keywords: CSPG4, immunotherapy, monoclonal antibody, cancer stem cells
Current Molecular Medicine
Title: CSPG4 in Cancer: Multiple Roles
Volume: 10 Issue: 4
Author(s): X. Wang, Y. Wang, L. Yu, K. Sakakura, C. Visus, J.H. Schwab, C.R. Ferrone, E. Favoino, Y. Koya, M.R. Campoli, J.B. McCarthy, A.B. DeLeo and S. Ferrone
Affiliation:
Keywords: CSPG4, immunotherapy, monoclonal antibody, cancer stem cells
Abstract: Chondroitin sulfate proteoglycan 4 (CSPG4), also known as High Molecular Weight- Melanoma Associated Antigen, is a cell surface proteoglycan which has been recently shown to be expressed not only by melanoma cells, but also by various types of human carcinoma and sarcoma. Furthermore, at least in squamous cell carcinoma of head and neck and in basal breast carcinoma, CSPG4 is expressed by cancer stem cells. CSPG4 plays an important role in tumor cell growth and survival. These CSPG4-associated functional properties of tumor cells are inhibited by CSPG4-specific monoclonal antibodies (mAb) in vitro. Moreover, CSPG4-specific mAb can also inhibit tumor growth and metastasis in vivo. The anti-tumor effects of CSPG4-specific mAb are likely to reflect the blocking of important migratory, mitogenic and survival signaling pathways in tumor cells. These results indicate that CSPG4 is a promising new target to implement mAb-based immunotherapy of various types of cancer.
Export Options
About this article
Cite this article as:
Wang X., Wang Y., Yu L., Sakakura K., Visus C., Schwab J.H., Ferrone C.R., Favoino E., Koya Y., Campoli M.R., McCarthy J.B., DeLeo A.B. and Ferrone S., CSPG4 in Cancer: Multiple Roles, Current Molecular Medicine 2010; 10 (4) . https://dx.doi.org/10.2174/156652410791316977
DOI https://dx.doi.org/10.2174/156652410791316977 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD147 Promotes Melanoma Progression Through Hypoxia-Induced MMP2 Activation
Current Molecular Medicine GIST and Breast Cancer: 3 Case Reports and a Review of the Literature
Current Cancer Therapy Reviews On The Edge of Validation – Cancer Protease Fibroblast Activation Protein
Mini-Reviews in Medicinal Chemistry Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Molecular Mechanisms of Tumor Invasion and Metastasis: An Integrated View
Current Molecular Medicine Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry Human Mesenchymal Stem Cells (hMSCs) as Targets of DNA Damaging Agents in Cancer Therapy
Current Cancer Drug Targets Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Research Progress of Exogenous Plant MiRNAs in Cross-Kingdom Regulation
Current Bioinformatics Nanoemulsions for Skin Targeting: Present Status and Future Prospects
Drug Delivery Letters Importance of Dietary Supplements to the Health
Current Nutrition & Food Science Structural and Functional Characterization of the Proteins Responsible for N<sup>6</sup>-Methyladenosine Modification and Recognition
Current Protein & Peptide Science Exploiting Internal Ribosome Entry Sites in Gene Therapy Vector Design
Current Gene Therapy Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Silver and Other Metals in the Treatment of Gastrointestinal Diseases
Current Medicinal Chemistry Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Targeting Microtubules for Cancer Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System
Current Cancer Drug Targets